Retinol, Orlistat, Phentermine: Anti-Obesity Treatments Before GLP-1s
From Mediator to Fen-Phen and rimonabant: the history of anti-obesity treatments and why GLP-1s represent a revolution.
Tirzépatide
GLP-1 Agonists: A Comprehensive Overview of Treatments Available in France
A comprehensive overview of GLP-1 agonists available in France in 2026: Mounjaro, Ozempic, Wegovy, Trulicity. Comparison, reimbursement, and future molecules.
GIP Receptors: The Key Difference of Mounjaro
GIP receptors are the key differentiating factor for Mounjaro. Their role in adipose tissue, the brain, and bones explains the superiority of tirzepatide.
Tirzepatide Half-Life: Why One Weekly Injection Is Enough
Tirzepatide Half-Life: How 3 Chemical Modifications Transform a 3-Minute Hormone into a Weekly Treatment. Pharmacokinetics Explained.
How Does Satiety Work with Tirzepatide?
How tirzepatide reduces appetite: mechanisms of satiety, food noise, neuronal signals. What patients experience and how to optimize.
Zepbound vs Mounjaro: Same Molecule, Different Indications
Zepbound and Mounjaro contain the same tirzepatide. What are the differences? Indications, reimbursement, availability in France. All you need to know in 2026.
Mounjaro vs Wegovy: Which Treatment to Choose in 2026?
Mounjaro vs Wegovy: complete 2026 comparison. Weight loss, side effects, cardiovascular benefits, cost. Which one to choose based on your profile?
Mounjaro vs Ozempic: Essential Pharmacological Differences
Mounjaro vs Ozempic: A comprehensive comparison of the two GLP-1 treatments. Efficacy, side effects, price, and selection criteria based on clinical studies.
Mounjaro Side Effects: What You Really Need to Know to Manage Them Better
Have you just started Mounjaro or has your doctor prescribed it to you? It’s completely normal to have questions about possible side effects. Rest assured, most Mounjaro side effects are predictable, temporary, and there are concrete ways to minimize them.
GLP-1 and GIP: Understanding the Two Hormones Targeted by Mounjaro
GLP-1 and GIP: discover the role of these two incretin hormones targeted by tirzepatide (Mounjaro). Mechanisms of action, differences, and synergy for weight loss.
Mounjaro (Tirzepatide): The New Revolutionary Treatment for Diabetes and Weight Loss in 2025
Mounjaro, with its active ingredient tirzepatide, marks a significant advancement in treating type 2 diabetes and obesity. This revolutionary drug, developed by Eli Lilly, received FDA approval in May 2022 and EMA approval in September 2022.
Tirzepatide: Mechanism of Action of the Dual GIP/GLP-1 Agonist
Discover the unique mechanism of action of tirzepatide, the first dual GIP/GLP-1 agonist. Learn how Mounjaro acts on the brain, pancreas, liver, and adipose tissue to produce superior weight loss compared to mono-agonists.